{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:50:27Z","timestamp":1782215427686,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["31971191"],"award-info":[{"award-number":["31971191"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200759"],"award-info":[{"award-number":["82200759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100557"],"award-info":[{"award-number":["82100557"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Large Instruments Open Foundation of Nantong University","award":["KFJN2375"],"award-info":[{"award-number":["KFJN2375"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The cell cycle mechanism is an integration point where information is sent through an upstream signaling network, making it a potential target for cancer diagnosis and treatment. The LAP1 protein, encoded by the <jats:italic>Tor1aip1<\/jats:italic> gene, is required to maintain the shape of the nuclear envelope and the progression of the cell cycle. The aim of this study was to determine the role of <jats:italic>Tor1aip1<\/jats:italic> gene in PRAD development and its mechanism. We analyzed the expression and survival data of TOR1 AIP1 in PRAD patients in the TCGA database and verified the low expression of TOR1 AIP1 in prostate cancer by qPCR, western blot and immunohistology, which was correlated with the tumor stage and survival prognosis of PRAD. In addition, lentiviral vectors were used to mediate the up-regulation or down-regulation of TOR1 AIP1 expression in prostate cancer cells, and the effects of TOR1 AIP1 on tumor proliferation and related signaling pathways were investigated by cell counting kit- 8, colony formation assay, transwell assay, western blot, and flow cytometry. As a result, we found that TOR1 AIP1 enhances protein stability of p53 by directly interacting with p53, consequently inhibited tumor proliferation and invasion by inducing the cell cycle to be arrested in the S phase. Therefore, TOR1 AIP1 represents a promising therapeutic target in PRAD due to its ability to stabilize p53 and enhance its tumor-suppressive functions. Future studies should focus on elucidating its mechanisms, developing targeted therapies, and exploring its clinical potential in combination with existing treatments. By advancing our understanding of TOR1 AIP1, we may unlock new strategies for improving outcomes in PRAD patients.<\/jats:p>","DOI":"10.1007\/s11010-025-05276-1","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:13:42Z","timestamp":1744128822000},"page":"4483-4497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TOR1 AIP1 interacts with p53 to enhance cell cycle dysregulation in prostate cancer progression"],"prefix":"10.1007","volume":"480","author":[{"given":"Zhaofeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanqun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suofei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"5276_CR1","doi-asserted-by":"publisher","first-page":"107719","DOI":"10.1016\/j.cmpb.2023.107719","volume":"240","author":"A Ram\u00edrez-Mena","year":"2023","unstructured":"Ram\u00edrez-Mena A, Andr\u00e9s-Le\u00f3n E, Alvarez-Cubero MJ, Anguita-Ruiz A, Martinez-Gonzalez LJ, Alcala-Fdez J (2023) Explainable artificial intelligence to predict and identify prostate cancer tissue by gene expression. Comput Methods Progr Biomed 240:107719. https:\/\/doi.org\/10.1016\/j.cmpb.2023.107719","journal-title":"Comput Methods Progr Biomed"},{"key":"5276_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. Cancer J Clin 70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"Cancer J Clin"},{"key":"5276_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvi\u00e8re O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79:243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"Eur Urol"},{"key":"5276_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3238\/arztebl.m2021.0026","volume":"118","author":"S Knipper","year":"2021","unstructured":"Knipper S, Ott S, Schlemmer HP, Grimm MO, Graefen M, Wiegel T (2021) Options for curative treatment of localized prostate cancer. Dtsch Arztebl Int 118:228\u2013236. https:\/\/doi.org\/10.3238\/arztebl.m2021.0026","journal-title":"Dtsch Arztebl Int"},{"key":"5276_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.21037\/tau.2017.12.08","volume":"7","author":"LC Mendez","year":"2018","unstructured":"Mendez LC, Morton GC (2018) High dose-rate brachytherapy in the treatment of prostate cancer. Transl Androl Urol 7:357\u2013370. https:\/\/doi.org\/10.21037\/tau.2017.12.08","journal-title":"Transl Androl Urol"},{"key":"5276_CR6","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.21037\/tau-20-1031","volume":"10","author":"KA D\u2019Rummo","year":"2021","unstructured":"D\u2019Rummo KA, Chen RC, Shen X (2021) Narrative review of management strategies and outcomes in node-positive prostate cancer. Transl Androl Urol 10:3176\u20133187. https:\/\/doi.org\/10.21037\/tau-20-1031","journal-title":"Transl Androl Urol"},{"key":"5276_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/iju.13512","volume":"25","author":"K Komura","year":"2018","unstructured":"Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW (2018) Current treatment strategies for advanced prostate cancer. Int J Urol 25:220\u2013231. https:\/\/doi.org\/10.1111\/iju.13512","journal-title":"Int J Urol"},{"key":"5276_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrm2147","volume":"8","author":"KH Vousden","year":"2007","unstructured":"Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275\u2013283. https:\/\/doi.org\/10.1038\/nrm2147","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5276_CR9","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","volume":"26","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor WA, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26:1268\u20131286. https:\/\/doi.org\/10.1101\/gad.190678.112","journal-title":"Genes Dev"},{"key":"5276_CR10","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1172\/jci70354","volume":"123","author":"MC Haffner","year":"2013","unstructured":"Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, G\u00fcrel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S (2013) Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123:4918\u20134922. https:\/\/doi.org\/10.1172\/jci70354","journal-title":"J Clin Invest"},{"key":"5276_CR11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","volume":"153","author":"SC Baca","year":"2013","unstructured":"Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA (2013) Punctuated evolution of prostate cancer genomes. Cell 153:666\u2013677. https:\/\/doi.org\/10.1016\/j.cell.2013.03.021","journal-title":"Cell"},{"key":"5276_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"5276_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.Ccr-09-0787","volume":"16","author":"ES Knudsen","year":"2010","unstructured":"Knudsen ES, Wang JY (2010) Targeting the RB-pathway in cancer therapy. Clin Cancer Res 16:1094\u20131099. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0787","journal-title":"Clin Cancer Res"},{"key":"5276_CR14","doi-asserted-by":"publisher","first-page":"188556","DOI":"10.1016\/j.bbcan.2021.188556","volume":"1876","author":"LJ Hern\u00e1ndez Borrero","year":"2021","unstructured":"Hern\u00e1ndez Borrero LJ, El-Deiry WS (2021) Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer 1876:188556. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188556","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"5276_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, Karimbayli J, Belletti B, Baldassarre G (2025) Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther 10:11. https:\/\/doi.org\/10.1038\/s41392-024-02080-z","journal-title":"Signal Transduct Target Ther"},{"key":"5276_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.eururo.2021.01.037","volume":"79","author":"H Li","year":"2021","unstructured":"Li H, Zhang Y, Li D, Ma X, Xu K, Ding B, Li H, Wang Z, Ouyang W, Long G, Zeng J, Liu H, Yan L, Zhang Y, Liu Z, Guan W, Hu Z, Liu C, Wan J, Wang G, Pu X, Zhang M, Guo L, An R, Qi J, Guo A, Ye Z, Liu J, Zhang X, Xu H (2021) Androgen receptor splice variant 7 predicts shorter response in patients with metastatic hormone-sensitive prostate cancer receiving androgen deprivation therapy. Eur Urol 79:879\u2013886. https:\/\/doi.org\/10.1016\/j.eururo.2021.01.037","journal-title":"Eur Urol"},{"key":"5276_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0962-8924(94)90067-1","volume":"4","author":"L Gerace","year":"1994","unstructured":"Gerace L, Foisner R (1994) Integral membrane proteins and dynamic organization of the nuclear envelope. Trends Cell Biol 4:127\u2013131. https:\/\/doi.org\/10.1016\/0962-8924(94)90067-1","journal-title":"Trends Cell Biol"},{"key":"5276_CR18","doi-asserted-by":"publisher","first-page":"8822","DOI":"10.1074\/jbc.270.15.8822","volume":"270","author":"L Martin","year":"1995","unstructured":"Martin L, Crimaudo C, Gerace L (1995) cDNA cloning and characterization of lamina-associated polypeptide 1C (LAP1C), an integral protein of the inner nuclear membrane. J Biol Chem 270:8822\u20138828. https:\/\/doi.org\/10.1074\/jbc.270.15.8822","journal-title":"J Biol Chem"},{"key":"5276_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/membranes6010008","author":"JB Serrano","year":"2016","unstructured":"Serrano JB, da Cruz ESOA, Rebelo S (2016) Lamina associated polypeptide 1 (LAP1) interactome and its functional features. Membranes. https:\/\/doi.org\/10.3390\/membranes6010008","journal-title":"Membranes"},{"key":"5276_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nature08869","volume":"464","author":"B Neumann","year":"2010","unstructured":"Neumann B, Walter T, H\u00e9rich\u00e9 JK, Bulkescher J, Erfle H, Conrad C, Rogers P, Poser I, Held M, Liebel U, Cetin C, Sieckmann F, Pau G, Kabbe R, W\u00fcnsche A, Satagopam V, Schmitz MH, Chapuis C, Gerlich DW, Schneider R, Eils R, Huber W, Peters JM, Hyman AA, Durbin R, Pepperkok R, Ellenberg J (2010) Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature 464:721\u2013727. https:\/\/doi.org\/10.1038\/nature08869","journal-title":"Nature"},{"key":"5276_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11010-014-2241-x","volume":"399","author":"M Santos","year":"2015","unstructured":"Santos M, Costa P, Martins F, da Cruz Silva EF, da Cruz Silva OA, Rebelo S (2015) LAP1 is a crucial protein for the maintenance of the nuclear envelope structure and cell cycle progression. Mol Cell Biochem 399:143\u2013153. https:\/\/doi.org\/10.1007\/s11010-014-2241-x","journal-title":"Mol Cell Biochem"},{"key":"5276_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.nmd.2014.04.007","volume":"24","author":"G Kayman-Kurekci","year":"2014","unstructured":"Kayman-Kurekci G, Talim B, Korkusuz P, Sayar N, Sarioglu T, Oncel I, Sharafi P, Gundesli H, Balci-Hayta B, Purali N, Serdaroglu-Oflazer P, Topaloglu H, Dincer P (2014) Mutation in TOR1AIP1 encoding LAP1B in a form of muscular dystrophy: a novel gene related to nuclear envelopathies. Neuromuscul Disord 24:624\u2013633. https:\/\/doi.org\/10.1016\/j.nmd.2014.04.007","journal-title":"Neuromuscul Disord"},{"key":"5276_CR23","doi-asserted-by":"publisher","first-page":"7030","DOI":"10.1128\/mcb.00322-06","volume":"26","author":"AJ Krieg","year":"2006","unstructured":"Krieg AJ, Hammond EM, Giaccia AJ (2006) Functional analysis of p53 binding under differential stresses. Mol Cell Biol 26:7030\u20137045. https:\/\/doi.org\/10.1128\/mcb.00322-06","journal-title":"Mol Cell Biol"},{"key":"5276_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3906\/biy-2010-39","volume":"45","author":"\u00d6F Erceylan","year":"2021","unstructured":"Erceylan \u00d6F, Sava\u015f A, G\u00f6v E (2021) Targeting the tumor stroma: integrative analysis reveal GATA2 and TORYAIP1 as novel prognostic targets in breast and ovarian cancer. Turk J Biol 45:127\u2013137. https:\/\/doi.org\/10.3906\/biy-2010-39","journal-title":"Turk J Biol"},{"key":"5276_CR25","doi-asserted-by":"publisher","first-page":"e11321","DOI":"10.7717\/peerj.11321","volume":"9","author":"D Zhang","year":"2021","unstructured":"Zhang D, Yan P, Han T, Cheng X, Li J (2021) Identification of key genes and biological processes contributing to colitis associated dysplasia in ulcerative colitis. PeerJ 9:e11321. https:\/\/doi.org\/10.7717\/peerj.11321","journal-title":"PeerJ"},{"key":"5276_CR26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"key":"5276_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H (2018) An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173:400\u2013416. https:\/\/doi.org\/10.1016\/j.cell.2018.02.052","journal-title":"Cell"},{"key":"5276_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.puhe.2019.04.016","volume":"172","author":"X Liu","year":"2019","unstructured":"Liu X, Yu C, Bi Y, Zhang ZJ (2019) Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health 172:70\u201380. https:\/\/doi.org\/10.1016\/j.puhe.2019.04.016","journal-title":"Public Health"},{"key":"5276_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433\u2013439. https:\/\/doi.org\/10.1001\/jama.294.4.433","journal-title":"JAMA"},{"key":"5276_CR30","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/ijc.28162","volume":"133","author":"N Shao","year":"2013","unstructured":"Shao N, Wang Y, Jiang WY, Qiao D, Zhang SG, Wu Y, Zhang XX, Wang JL, Ding Y, Feng NH (2013) Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer. Int J Cancer 133:1743\u20131750. https:\/\/doi.org\/10.1002\/ijc.28162","journal-title":"Int J Cancer"},{"key":"5276_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2019.00603","volume":"10","author":"N Vitkin","year":"2019","unstructured":"Vitkin N, Nersesian S, Siemens DR, Koti M (2019) The tumor immune contexture of prostate cancer. Front Immunol 10:603. https:\/\/doi.org\/10.3389\/fimmu.2019.00603","journal-title":"Front Immunol"},{"key":"5276_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","volume":"6","author":"WP Harris","year":"2009","unstructured":"Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76\u201385. https:\/\/doi.org\/10.1038\/ncpuro1296","journal-title":"Nat Clin Pract Urol"},{"key":"5276_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/MOU.0b013e328329b73a","volume":"19","author":"EM Van Allen","year":"2009","unstructured":"Van Allen EM, Ryan CJ (2009) Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol 19:315\u2013321. https:\/\/doi.org\/10.1097\/MOU.0b013e328329b73a","journal-title":"Curr Opin Urol"},{"key":"5276_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/go.20.00511","volume":"7","author":"FC Maluf","year":"2021","unstructured":"Maluf FC, Pereira FMT, Silva AG, Dettino ALA, Cardoso APG, Sasse AS, Soares A, Kann AG, Herchenhorn D, Jardim DLF, Cort\u00e9s DEL, Kater FR, Morbeck IAP, Reolon JFN, Rinck JA Jr, Zarb\u00e1 JJ, Sade JP, da Trindade KM, Costa L, Dos Santos LV, Maia MC, Siqueira MB, Gillessen S (2021) Consensus on the treatment and follow-up for metastatic castration-resistant prostate cancer: a report from the first global prostate cancer consensus conference for developing countries (PCCCDC). JCO Glob Oncol 7:559\u2013571. https:\/\/doi.org\/10.1200\/go.20.00511","journal-title":"JCO Glob Oncol"},{"key":"5276_CR35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13023-014-0174-9","volume":"9","author":"I Dorboz","year":"2014","unstructured":"Dorboz I, Coutelier M, Bertrand AT, Caberg JH, Elmaleh-Berg\u00e8s M, Lain\u00e9 J, Stevanin G, Bonne G, Boespflug-Tanguy O, Servais L (2014) Severe dystonia, cerebellar atrophy, and cardiomyopathy likely caused by a missense mutation in TOR1AIP1. Orphanet J Rare Dis 9:174. https:\/\/doi.org\/10.1186\/s13023-014-0174-9","journal-title":"Orphanet J Rare Dis"},{"key":"5276_CR36","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41598-020-58051-1","volume":"10","author":"J Zhu","year":"2020","unstructured":"Zhu J, Singh M, Selivanova G, Peuget S (2020) Pifithrin-\u03b1 alters p53 post-translational modifications pattern and differentially inhibits p53 target genes. Sci Rep 10:1049. https:\/\/doi.org\/10.1038\/s41598-020-58051-1","journal-title":"Sci Rep"},{"key":"5276_CR37","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1349-7006.2009.01150.x","volume":"100","author":"K Kojima","year":"2009","unstructured":"Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H (2009) Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci 100:1128\u20131136. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01150.x","journal-title":"Cancer Sci"},{"key":"5276_CR38","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/jcmm.14878","volume":"24","author":"S Chen","year":"2020","unstructured":"Chen S, Zhou Q, Guo Z, Wang Y, Wang L, Liu X, Lu M, Ju L, Xiao Y, Wang X (2020) Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1\/S cell cycle arrest via the ATM\/CHK2\/p53 pathway. J Cell Mol Med 24:1804\u20131821. https:\/\/doi.org\/10.1111\/jcmm.14878","journal-title":"J Cell Mol Med"},{"key":"5276_CR39","doi-asserted-by":"publisher","first-page":"e12341","DOI":"10.1371\/journal.pone.0012341","volume":"5","author":"D Nantajit","year":"2010","unstructured":"Nantajit D, Fan M, Duru N, Wen Y, Reed JC, Li JJ (2010) Cyclin B1\/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response. PLoS ONE 5:e12341. https:\/\/doi.org\/10.1371\/journal.pone.0012341","journal-title":"PLoS ONE"},{"key":"5276_CR40","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","volume":"31","author":"LT Chen","year":"2020","unstructured":"Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY (2020) Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol 31:334\u2013351. https:\/\/doi.org\/10.1016\/j.annonc.2019.12.001","journal-title":"Ann Oncol"},{"key":"5276_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2018.11.019","volume":"443","author":"B Xie","year":"2019","unstructured":"Xie B, Wang S, Jiang N, Li JJ (2019) Cyclin B1\/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance. Cancer Lett 443:56\u201366. https:\/\/doi.org\/10.1016\/j.canlet.2018.11.019","journal-title":"Cancer Lett"},{"key":"5276_CR42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.canlet.2019.05.036","volume":"459","author":"L Fang","year":"2019","unstructured":"Fang L, Du WW, Awan FM, Dong J, Yang BB (2019) The circular RNA circ-Ccnb1 dissociates Ccnb1\/Cdk1 complex suppressing cell invasion and tumorigenesis. Cancer Lett 459:216\u2013226. https:\/\/doi.org\/10.1016\/j.canlet.2019.05.036","journal-title":"Cancer Lett"},{"key":"5276_CR43","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41418-023-01180-7","volume":"30","author":"J Yi","year":"2023","unstructured":"Yi J, Li H, Chu B, Kon N, Hu X, Hu J, Xiong Y, Kaniskan HU, Jin J, Gu W (2023) Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1. Cell Death Differ 30:1799\u20131810. https:\/\/doi.org\/10.1038\/s41418-023-01180-7","journal-title":"Cell Death Differ"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05276-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05276-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05276-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T07:17:58Z","timestamp":1752563878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05276-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["5276"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05276-1","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The studies in which human prostate tumor samples were collected were approved by the ethical committees of the Affiliated Hospital of Qingdao University (No: QYFYW-ZLL26555).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The published literature was used to obtain all datasets, so it was confirmed that all written informed consent was obtained. All patients and medical personnel gave their written consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All animal study protocols were approved by the Ethics Committee of the Medical Animal Laboratory of the Affiliated Hospital of Qingdao University (No: AHQU-MAL20230512).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving animal participants"}}]}}